FIELD: chemistry.
SUBSTANCE: invention relates to biochemistry. Described are antibodies and fragments thereof, having high affinity for human α-synuclein protofibrils and low binding of α-synuclein monomers. Disclosed are compositions which contain the described antibody or a fragment thereof, methods of detecting α-synuclein protofibrils using the described antibody or fragment thereof. In other versions, the present invention relates to methods of preventing, slowing down the development or treating a neurodegenerative disorder with α-synuclein pathology, where said methods include administering the described antibody or fragment thereof. The invention also relates to use of said antibody or fragment thereof to obtain a pharmaceutical composition for treating a neurodegenerative disorder with α-synuclein pathology.
EFFECT: invention is used for diagnosis or monitoring of the development of a neurodegenerative disorder with α-synuclein pathology, and in methods of reducing or inhibiting α-synuclein aggregation by administering said antibody or fragment thereof.
31 cl, 9 dwg, 4 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMPROVED PROTOFIBRIL-SELECTIVE ANTIBODIES AND USE THEREOF | 2007 |
|
RU2429244C2 |
| ANTIBODIES THAT BIND TO α-SYNUCLEIN PROTOFIBRILS | 2021 |
|
RU2810587C1 |
| AGENTS, APPLICATION WAYS AND METHODS FOR TREATING SYNUCLEOPATHY | 2016 |
|
RU2765303C2 |
| IMPROVED ANTIBODIES BINDING Aβ-PROTOFIBRILS | 2015 |
|
RU2700104C2 |
| MONOCLONAL ANTIBODIES TO ALPHA-SYNUCLEIN FOR PREVENTING TAU-PROTEIN AGGREGATION | 2017 |
|
RU2760334C2 |
| ANTIBODIES TO ALPHA-SYNUCLEIN AND OPTIONS OF THEIR USE | 2019 |
|
RU2812765C2 |
| ANTIBODIES | 2018 |
|
RU2798399C2 |
| ANTIBODIES AGAINST ALPHA SYNUCLEIN | 2018 |
|
RU2787039C2 |
| HUMANISED ANTIBODIES TO β-AMYLOID PEPTIDE | 2008 |
|
RU2475500C2 |
| HUMANISED ANTI-TAU ANTIBODIES | 2015 |
|
RU2743152C2 |
